Lipoprotein (Lp) [a] consists of a low-density lipoprotein (LDL) like moiety bound to a highly glycosylated apolipoprotein (a) particle and an apolipoprotein B-100 particle linked via a single disulfide bond (Figure 1). Since its discovery in 1963 by Kare Berg, Lp(a) has gone relatively unnoticed in cardiovascular (CV) risk reduction algorithms (1). More recently, greater attention has been afforded to Lp(a) with growing evidence suggesting its causality in the development of atherosclerotic cardiovascular disease (ASCVD), culminating in a recent consensus statement published by the ESC (2).
Author Sub-editor: Dr May Hu Dr May Hu is a cardiology trainee in the North West deanery. She graduated with First Class Honours from the University
Author Sub-editor: Dr Jhiamluka Solano Dr Jhiamluka Solano is a cardiology resident doctor (ST6) in the Yorkshire and Humber Deanery, currently undertaking a DPhil (PhD)
Author Sub-editor: Dr Justin Chiong Dr Justin Chiong is an NIHR Academic Clinical Fellow and Cardiology Registrar in the North West Deanery. He graduated from
Author Heartbeat Sub-Editor: Marina Zafeiri Dr Marina Zafeiri is an IMT3 in the Wessex deanery, with a strong interest in Cardiology. She graduated from Athens
Author Heartbeat Sub-Editor: Toby MacCarthy Author: Toby MacCarthy
Author Heartbeat Sub-Editor: Toby MacCarthy Author: Toby MacCarthy
